SOMNF (SomnoMed) Other Stockholders Equity: $0.00 Mil (As of Dec. 2025)


SOMNF SomnoMed Ltd SOMNF
49 GF Score
Price $0.45
GF Value $0.40
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Other Stockholders Equity?

SomnoMed SOMNF 49 Other Stockholders Equity is $0.00 Mil as of Dec. 2025. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.40 (Significantly Overvalued). The stock has 3 warning signs investors should review.

SomnoMed's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $0.00 Mil.

SomnoMed's quarterly Other Stockholders Equity increased from Dec. 2024 ($-0.00 Mil) to Jun. 2025 ($0.00 Mil) and increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

SomnoMed's annual Other Stockholders Equity declined from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Jun. 2025 ($0.00 Mil).

SomnoMed Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for SomnoMed's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed Other Stockholders Equity Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 0.00
SOMNF
49GF Score
SomnoMed Ltd SOMNF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SomnoMed Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
SomnoMed (SOMNF) has a Other Stockholders Equity of $0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on SomnoMed and its competitors.
Is SomnoMed's Other Stockholders Equity too high?
SomnoMed's current Other Stockholders Equity is $0.00 Mil. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Other Stockholders Equity compare to ABT and SYK?
SomnoMed's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on SomnoMed and its competitors. SomnoMed's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.40, compared to a current price of $0.45 — trading 12% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For SomnoMed (SOMNF), the current Other Stockholders Equity is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of $0.45 is trading 12% above its estimated GF Value™ of $0.40. GuruFocus considers SomnoMed to be Significantly Overvalued.

Key valuation signals for SOMNF:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $0.40 vs. price of $0.45 (12% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for SOMNF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.40
GF Value